1. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–324.
2. Pyörälä K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandivanvian Simvastatin Survival Study 4S). Diabetes Care 1997, 20:614–620.
3. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001–1009.
4. Semenkovich CF: Diabetic dyslipidemia: pathophysiology and treatment. In Ellenberg and Rifkin's Diabetes Mellitus, edn 6. Edited by Porte D, et al. New York: McGraw-Hill; 2002:805–813.
5. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; 2001. NIH Publication 01-3670. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed April 1, 2003. The ATP III report includes the NCEP practice guidelines and reviews the research base supporting the guidelines. The Therapeutic Lifestyle Changes section reviews the literature supporting the guidelines and emerging issues. The appendices to the section provide sample menus and other tools.